← MediWound Ltd. (MDWD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MediWound Ltd. (MDWD)
Medicinal Chemicals & Botanical Products · market cap $176M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-19 (est.)
Earnings
Pipeline
8
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
MediWound Ltd. (MDWD) is a small-cap Israeli biotech (~$179M market cap, 111 employees) focused on enzymatic debridement and wound-care biologics. Its lead clinical assets include NexoBrid and DGD (Phase 3, burns) and EscharEx (EX-03) in a Phase 3 trial for venous leg ulcers (VLU), with the EX-03 VLU readout expected around December 2026 rated as a high-importance catalyst.
The catalyst path
- 2026-11-19 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · EscharEx (EX-03)imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EscharEx 5% (EX-02 formulation) | Phase 2 | Superficial Basal Cell Carcinoma |
| EscharEx (5% EX-02 formulation) | Phase 2 | Venous Leg Ulcer |
| EscharEx (EX-02 formulation) | Phase 2 | Venous Leg Ulcer |
| DGD | Phase 3 | Burn |
| EscharEx | Phase 2 | Hard to Heal Wounds |
| Gel Vehicle | Phase 3 | Thermal Burns |
| EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) |
| NexoBrid | Phase 3 | Thermal Burns |
Price & technical context
3-month
-10.3%
6-month
-16.0%
12-month
-24.5%
52-wk range
$12.61–$19.69
vs 50-day MA
-0.2%
vs 200-day MA
-14.2%
Realized vol
40.0%
Max drawdown
-43.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MDWD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.